What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dosing
Page 14 of 31 of this archive, newest first.
SURMOUNT-2 was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Pancreatitis, obstruction, gallbladder: three things nausea can be
A small number of serious gastrointestinal events occur in people taking these drugs. Distinguishing them from the expected effect profile is the most consequential…
The restart nobody plans for
We work through the residual-exposure table so the decision can be made from numbers rather than from feel.
Four millimetres is enough, and the data says so
The insulin injection-technique literature is large, well conducted and directly transferable on questions of depth and tissue. We say where it stops transferring.
The mechanism behind the mechanism
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The United Kingdom pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
South Korea pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Mapping a rotation that you will actually follow
A rotation scheme that is too complicated will not be followed. We describe the simple ones that are.
From cell to clinic: where the extrapolation stops being safe
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
Units, millilitres, milligrams: three scales on one small object
We work through the arithmetic in full, because it is short, and because the errors it prevents are order-of-magnitude errors.
Saudi Arabia pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Coming off: what the pharmacology permits
What a slow reduction could plausibly buy, and what it certainly cannot prevent.
The eighteenth month, and the conversation that should have happened in the third
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
The convention nobody explains before handing over the vial
Insulin syringes are graduated in units on a convention that fixes 100 units to one millilitre. That convention says nothing about how much peptide is in a unit, and…
Holding a dose is a decision, not a failure
Every major phase 3 protocol in this class allowed escalation to be delayed for tolerability. Almost no product label explains the mechanics of doing so.
Gallstones during rapid weight loss: drug, or weight loss?
The features that should prompt urgent assessment, stated once and plainly.
The mechanism behind the mechanism
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
What the new Mexico guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.